Secondary MR is not a milder version of primary MR
Secondary MR is not primarily a leaflet disease. It occurs when LV or LA remodeling prevents structurally intact leaflets from coapting normally. Applying primary MR logic to secondary MR leads to errors in both severity interpretation and treatment strategy.
When an echo report says severe MR, the first question is not only how severe — it is primary or secondary. The same label can describe very different mechanisms, treatment targets, evidence bases, and perioperative risks. In the perioperative setting, missing this distinction can drive the wrong preoperative conversation.
Key takeaway
Secondary MR is a remodeling disease in which the mitral valve leaks because LV or LA geometry has changed. Primary MR is a valve-apparatus disease in which the ventricle responds to chronic volume overload. The same EROA value, qualitative grade, or color Doppler appearance does not carry the same clinical meaning in both pathways.
Key points
- Primary MR is caused by structural disease of the mitral valve apparatus — leaflet, chordal, or annular pathology is the primary problem.
- Secondary MR is caused by LV or LA remodeling that prevents normal leaflet coaptation, often with structurally intact leaflets.
- In primary MR, the valve is the main treatment target. In secondary MR, the starting point is the underlying ventricular or atrial remodeling and the clinical substrate driving it.
- The same EROA carries different prognostic meaning in secondary MR because the regurgitation occurs in an already remodeled or failing ventricle.
- Perioperatively, secondary MR should trigger assessment of HF stability, pulmonary pressure, RV function, LV reserve, and GDMT optimization — not only valve repairability.
When to read this
An echo report shows significant MR but the mechanism is unclear — or you need to frame whether the perioperative risk is driven by the valve, the ventricle, or both.
The fundamental difference in mechanism
Primary MR means the mitral valve apparatus itself is the primary pathology. Myxomatous prolapse, a flail segment from ruptured chordae, leaflet perforation from endocarditis, or rheumatic restriction — in each case, structural leaflet or chordal abnormality prevents coaptation. The LV then adapts to chronic volume overload with dilation and eccentric remodeling.
Secondary MR occurs when LV or LA geometry changes enough that the leaflets can no longer coapt normally, even if the leaflets themselves are structurally intact. In ventricular functional MR, LV dilation displaces the papillary muscles outward and apically, tethering the leaflets away from the coaptation point. In atrial functional MR, longstanding AF or HFpEF can enlarge the LA and annulus, producing MR despite preserved LV systolic function.
Why the same number means different things
In primary MR, the LV may initially be structurally normal and then adapts to chronic regurgitant volume over time. In secondary MR, regurgitation occurs in the setting of an already remodeled or failing ventricle. Therefore, the same EROA does not necessarily carry the same hemodynamic or prognostic meaning. An EROA of 0.30 cm² in a patient with LVEF 25% and HFrEF carries a different burden than EROA 0.30 cm² in a structurally normal heart.
ACC/AHA 2020 maintains the same quantitative severe range for secondary MR as for primary MR: EROA ≥ 0.40 cm² and regurgitant volume ≥ 60 mL/beat. However, outcome studies in secondary MR populations have shown adverse outcomes at lower EROA values, around 0.20 cm². This is a prognostic signal in a vulnerable LV population — not a guideline redefinition of severe MR. EROA 0.20 cm² is not severe secondary MR by ACC/AHA criteria, but it should not be dismissed when LV dysfunction or advanced remodeling is present.
The treatment target is different
In primary MR, valve repair or replacement directly treats the mechanism by eliminating the regurgitant orifice. If performed before irreversible LV dysfunction, the LV can recover from the volume overload.
In secondary MR, treating the valve does not treat the underlying ventricular or atrial disease. The MR is a consequence of myocardial, ventricular, or atrial remodeling. For this reason, guideline-directed medical therapy comes first: ACEi/ARB/ARNI, beta-blockers, MRA, SGLT2 inhibitors, and diuretics are used to treat HF, manage congestion, and in some patients promote reverse remodeling. CRT may also reduce MR when dyssynchrony contributes to tethering.
Perioperative perspective
When preoperative TTE shows significant MR, the perioperative question changes with the mechanism. For primary MR: Is the valve disease severe enough to require valve-team or cardiac surgery consultation before the elective procedure? For secondary MR: Is HF stable? Has GDMT been optimized? Are LV size and function stable? Is pulmonary hypertension present? Is RV function preserved? Could anesthesia or surgical stress unmask limited hemodynamic reserve? Secondary MR perioperative risk should be assessed not only through the valve but through HF stability, pulmonary circulation, RV function, and overall hemodynamic reserve.
Do not apply primary MR repair-first thinking to secondary MR
In primary MR, timely repair before irreversible LV dysfunction is a central goal. In secondary MR, the valve is not the starting point of the disease — LV or LA remodeling is. Framing secondary MR as a valve that needs repair before assessing GDMT, HF stability, and the remodeling substrate is not consistent with ACC/AHA 2020 management principles.
Apply this in practice
Use the Secondary MR Severity Tool to assess severity in the context of ventricular or atrial remodeling.
Secondary MR Severity Tool